Clinical integration
Maximising patient data for better cancer care.

Clinical integration involves creating a seamless connection between clinical and discovery science to maximise the value of patient data and samples.
Our goal is to foster close collaboration between researchers and clinicians, designing experiments and clinical trials that enhance both scientific understanding and cancer patient outcomes.
Prof James Brenton leads a partnership between Addenbrooke’s Hospital, GE Healthcare, and the University of Cambridge to develop the GE Edison Health Services platform. This platform integrates data from electronic health records, radiology, and genomic results, making patient information easily accessible in one place. AI algorithms on this platform help to refine and explain patient data, aiding clinicians in their decisions.
The IMAXT Cancer Grand Challenge, led by Prof Greg Hannon, has created the first 3D tumour virtual reality tool by bringing together experts from diverse fields such as medicine, molecular biology, astronomy and programming. This innovative tool aims to provide a comprehensive view of a patient’s tumour structure and behaviour.
For the Wellcome LEAP Delta Tissue project, the Hannon Group is studying samples from patients with Triple Negative Breast Cancer before and after treatment. They are collecting data from these samples and combining it with information from other methods to create a model that predicts how patients will respond to treatments based on their initial samples.
We aim to develop an integrated discovery ecosystem that ensures patient data and samples are used to their fullest potential. We are focused on ensuring that any diagnostic or predictive tools we develop are ready for use in clinical settings. This means designing these tools to meet the standards required for certification as medical devices from the start of the project. In our biomarker studies, we plan extensive validation and ensure the procedures used are clinically certified, making them reliable and ready for patient care.
By integrating clinical and discovery science we aim to improve cancer research and treatment, ultimately improving patient outcomes.
Impact
See all case studies-
Improving early detection of cancer with hyperspectral endoscopy
The Bohndiek Group have developed advanced imaging technology to improve early detection of esophageal cancer in patients with Barrett’s oesophagus.
Find out more -
Personalising treatment for ovarian cancer patients: BriTROC-2
BriTROC-2 is a nationwide project developing personalised treatments for women diagnosed with High Grade Serous Ovarian Cancer.
Find out more
Related News
See all news-
$6.5 million awarded to develop precision breast cancer research in Cambridge
30th October 2023
The project aims to help doctors predict the best treatment for patients with high-risk breast cancers.
Find out more -
Minderoo Precision Brain Tumour Programme tops recruitment milestones
9th May 2023
The Minderoo Precision Brain Tumour Programme is providing patients in the UK with access to a new level of innovation and excellence in treatment and
Find out more -
Pioneering new ways to diagnose childhood brain tumours trialled by researchers in Cambridge
20th March 2023
Dr Jessica Taylor has been awarded a Future Leaders Award to develop novel techniques to distinguish different types of medulloblastoma.
Find out more